Simpson Thacher represented the underwriters, J.P. Morgan Securities LLC, Goldman Sachs & Co LLC and Cowen and Company, LLC, in connection with the initial public offering by Frequency Therapeutics, Inc. (“Frequency”) of 6,000,000 shares of its common stock, which raised approximately $84 million in gross proceeds. The initial public offering closed on October 7, 2019.
Frequency is a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Frequency’s progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies.
The Simpson Thacher team for this transaction included Art Robinson, Jean Park, Kirsten Harmon and Jessica Jeong (Capital Markets); Vanessa Burrows (Healthcare); Larry Moss, Caitlin Lucey and Erik Ward (Executive Compensation and Employee Benefits); Karen Hsu Kelley and Shari Ness (Public Company Advisory Practice); Jonathan Cantor and Jasmine Hay (Tax); Andrew Pagliughi (FINRA & Blue Sky); Mike Isby (Environmental); and Lori Lesser, Alysha Sekhon and Genevieve Dorment (IP).